Review Article: Tumor Markers, Types and Clinical Applications
DOI:
https://doi.org/10.24237/ASJ.03.02.941CAbstract
Over the past ten years, tumor markers have played an increasingly important role in clinical
oncology. This trend is expected to continue as technology advances and our knowledge of the
human body and disease processes grows. In the treatment of cancer, tumor markers are widely
used for a variety of purposes, including screening, selecting a management strategy,
determining the prognosis, and post-therapy follow-up. A comprehensive of the fundamentals
of pathophysiology and identification strategies for each specific malignancy is necessary for
their prudent application in clinical practice. Oncology's use of cancer biomarkers has
transformed the way that cancer is treated, and led to notable improvements in patient outcomes
and cancer treatment.
References
[1] S. Das, MK. Dey, R. Devireddy, MR. Gartia, Biomarkers in Cancer Detection, Diagnosis, and Prognosis, Sensors (Basel), 24(1),37(2023), DOI(https://doi.org/10.3390/s24010037)
[2] MJ. Duffy, Role of tumor markers in patients with solid cancers: A critical review, Eur J Intern Med, 18(3), 175-84(2007), DOI(https://doi.org/10.1016/j.ejim.2006.12.001)
[3] A. Passaro, M. Al Bakir, EG. Hamilton, M. Diehn, F. André, S. Roy-Chowdhuri, G. Mountzios, II. Wistuba, C. Swanton, and S. Peters, Cancer biomarkers: Emerging trends and clinical implications for personalized treatment, Cell, 28,187(7), 1617-1635(2024), DOI(https://doi.org/10.1016/j.cell.2024.02.041)
[4] MJ. Duffy, J. Crown, A personalized approach to cancer treatment: how biomarkers can help, Clinical Chemistry, 54(11), 1770-9(2008), DOI(https://doi.org/10.1373/clinchem.2008.110056)
[5] AJ. Paterson, J. Schlom, HF. Sears, J. Bennett, D. Colcher, A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72.3., Int J Cancer, 15,37(5), 659-66(1986), DOI(https://doi.org/10.1002/ijc.2910370504)
[6] B. Akverdi, O. Erbaş Tumor markers and clinical use Demiroglu Science University Florence Nightingale, Journal of Transplantation, 6(1-2),29-36(2021), DOI(10.5606/dsufnjt.2021.023)
[7] Y. Zhou, L. Tao, J. Qiu, Tumor biomarkers for diagnosis, prognosis and targeted therapy, Sig Transduct Target Ther 9, 132 (2024), DOI(https://doi.org/10.1038/s41392-024-01823-2)
[8] MJ. Duffy, Use of Biomarkers in Screening for Cancer, EJIFCC, 25, 21(1),1-12(2010)
[9] BK. Prasanth, S. Alkhowaiter, G. Sawarkar, BD. Dharshini, A. R. Baskaran, Unlocking Early Cancer Detection: Exploring Biomarkers, Circulating DNA, and Innovative Technological Approaches, Cureus,15(12),e51090(2023), DOI(10.7759/cureus.51090)
[10] MJ. Duffy, Tumor markers in clinical practice: a review focusing on common solid cancers, Med Princ Pract, 22(1), 4-11(2013), DOI(10.1159/000338393)
[11] D. van den Broek, HJM. Groen, S. Holdenrieder, H. van Rossum, M. van den Heuvel, Screening approaches for lung cancer by blood-based biomarkers: Challenges and opportunities, Tumor Biology, 46(s1),S65-S80(2024), DOI(https://doi.org/10.3233/TUB-230004)
[12] J. Glowska-Ciemny, J. Pankiewicz, Z. Malewski, C. von Kaisenberg, R. Kocylowski, Alpha-fetoprotein (AFP) - new aspects of a wellknown marker in perinatology, Ginekologia Polska, 93, 1, 70–75(2022), DOI(https://doi.org/10.5603/gp.a2021.0226)
[13] D. Betz, K. Fane, Human Chorionic Gonadotropin, In: StatPearls, (Treasure Island (FL): StatPearls Publishing, 2025)
[14] VL. Kankanala, M. Zubair, SKR. Mukkamalla, Carcinoembryonic Antigen, In: StatPearls, (Treasure Island (FL): StatPearls Publishing, 2025)
[15] B.V. Madhavi, B. Ravishankar, and B. Raj, Tumor markers - a diagnostic tool in solid cancers, Indian Journal of Basic and Applied Medical Research, 9, (2020), DOI(10.36848/IJBAMR/2020/12114.51259)
[16] M. da Silva, N. Yoshiki, H. Adnan, C. Diana, Y. Zhang, T. Mads, P. Pedro, M. Ulla, B. Eric, V. Sergey, L. Steven, D. Leonor, C. Henrik, Characterization of Binding Epitopes of CA125 Monoclonal Antibodies, Journal of proteome research, 13, (2014), DOI(10.1021/pr500215g)
[17] VK. Shukla, G. D. Sharma, VK. Dixit, Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder, Trop Gastroenterol, 27(4),160-5(2006)
[18] K. Thriveni, L. Krishnamoorthy, G. Ramaswamy, Correlation study of Carcino Embryonic Antigen & Cancer Antigen 15.3 in pretreated female breast cancer patients, Indian J Clin Biochem, 22(1),57-60(2007), DOI(https://doi.org/10.1007/BF02912882)
[19] R. JagadishPrasad, CD. Mouneshkumar, R. InduCherangapadath, N. Bhupender, M. Deepthi, H. Sahar, R. Vivek, Tumor markers in oral cancer: A review, Journal of Family Medicine and Primary Care, 9, 492(2020), DOI(https://doi.org/10.4103/jfmpc.jfmpc_1036_19)
[20] HECD. Silva, GNM. Santos, AF. Leite, CRM. Mesquita, PTS. Figueiredo, CM. Stefani, NS. de Melo, The use of artificial intelligence tools in cancer detection compared to the traditional diagnostic imaging methods: An overview of the systematic reviews, PLoS One, 18(10),e0292063(2023), DOI(https://doi.org/10.1371/journal.pone.0292063)
[21] WL. Bi, A. Hosny, MB. Schabath, ML. Giger, NJ. Birkbak, A. Mehrtash, T. Allison, O. Arnaout, C. Abbosh, IF. Dunn, RH. Mak, RM. Tamimi, CM. Tempany, C. Swanton, U. Hoffmann, LH. Schwartz, RJ. Gillies, RY. Huang, HJWL. Aerts, Artificial intelligence in cancer imaging: Clinical challenges and applications, CA Cancer J Clin, 69(2),127-157(2019), DOI(https://doi.org/10.3322/caac.21552)
Downloads
Published
Versions
- 2025-06-11 (2)
- 2025-04-29 (1)
Issue
Section
License
Copyright (c) 2025 CC BY 4.0

This work is licensed under a Creative Commons Attribution 4.0 International License.